Overview

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment

Phase:

Phase 3

Details

Lead Sponsor:

Zai Lab (Shanghai) Co., Ltd.

Treatments:

Niraparib